WHOLE EXOME SEQUENCING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Whole Exome Sequencing Market, By Product Type (Instruments, Consumables, and Services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, and Other Technologies), By Application (Drug Discovery & Development, Clinical Diagnostics, and Research), By Indication (Cancer, Rare/Inherited Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, and Others), By End User (Hospitals & Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Biopharmaceutical Companies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On July 30, 2024, GeneDx, a biotech commercial company, improved its Whole Genome Sequencing (WGS) service with faster turnaround (5 days), expanded sample options (buccal swabs), and more repeat expansions covered. These upgrades aim to speed diagnoses, particularly for rare diseases, improving patient outcomes.
In May 2024, SOPHiA GENETICS, a leader in data-driven medicine, joined forces with tech giants, Microsoft and NVIDIA, to transform healthcare with an advanced, scalable whole genome sequencing (WGS) analytics solution. This collaboration aims to make the solution available to healthcare providers by the end of the year.
In February 2023, Illumina Inc., a biotechnology company, announced the delivery of its first NovaSeqX Plus system to the Broad Institute. The platform is designed to support research groups accessing sequencing services including the company's human whole genome product and its combined genome/exome product.
In January 2023, QIAGEN Digital Insights (QDI), the bioinformatics arm of QIAGEN, launched an upgraded version of the QIAGEN CLC Genomics Workbench Premium. This enhanced platform is designed to address data-analysis bottlenecks in next-generation sequencing (NGS), offering significant improvements in analysis speed for more efficient interpretation of whole genome sequencing (WGS), whole exome sequencing, and large panel sequencing data.